Title |
Multiple Intravenous Administrations of Human Umbilical Cord Blood Cells Benefit in a Mouse Model of ALS
|
---|---|
Published in |
PLOS ONE, February 2012
|
DOI | 10.1371/journal.pone.0031254 |
Pubmed ID | |
Authors |
Svitlana Garbuzova-Davis, Maria C. O. Rodrigues, Santhia Mirtyl, Shanna Turner, Shazia Mitha, Jasmine Sodhi, Subatha Suthakaran, David J. Eve, Cyndy D. Sanberg, Nicole Kuzmin-Nichols, Paul R. Sanberg |
Abstract |
A promising therapeutic strategy for amyotrophic lateral sclerosis (ALS) is the use of cell-based therapies that can protect motor neurons and thereby retard disease progression. We recently showed that a single large dose (25 × 10⁶ cells) of mononuclear cells from human umbilical cord blood (MNC hUCB) administered intravenously to pre-symptomatic G93A SOD1 mice is optimal in delaying disease progression and increasing lifespan. However, this single high cell dose is impractical for clinical use. The aim of the present pre-clinical translation study was therefore to evaluate the effects of multiple low dose systemic injections of MNC hUCB cell into G93A SOD1 mice at different disease stages. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
United Kingdom | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 2 | 3% |
Germany | 1 | 2% |
United Kingdom | 1 | 2% |
Unknown | 59 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 15 | 24% |
Student > Bachelor | 12 | 19% |
Student > Master | 10 | 16% |
Researcher | 7 | 11% |
Professor | 3 | 5% |
Other | 12 | 19% |
Unknown | 4 | 6% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 21 | 33% |
Medicine and Dentistry | 14 | 22% |
Biochemistry, Genetics and Molecular Biology | 6 | 10% |
Neuroscience | 5 | 8% |
Nursing and Health Professions | 3 | 5% |
Other | 7 | 11% |
Unknown | 7 | 11% |